Diffuse Intrinsic Pontine Glioma (DIPG) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Midatech, Celgene, Oncotelic

Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 25+ key pharma and biotech companies are working on 25+ pipeline drugs in the Diffuse Intrinsic Pontine Glioma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Diffuse Intrinsic Pontine Glioma (DIPG) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Diffuse Intrinsic Pontine Glioma Market

The Diffuse Intrinsic Pontine Glioma Pipeline report embraces in-depth commercial, regulatory, and Diffuse Intrinsic Pontine Glioma clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Diffuse Intrinsic Pontine Glioma drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Diffuse Intrinsic Pontine Glioma (DIPG) Pipeline Analysis

The report provides insights into: 

The report provides detailed insights into the emerging therapies for Diffuse Intrinsic Pontine Glioma treatment and the aggregate therapies developed by major pharma companies.

It accesses the different Diffuse Intrinsic Pontine Glioma therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

It outlines the major Diffuse Intrinsic Pontine Glioma companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

The report evaluates the Diffuse Intrinsic Pontine Glioma drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Diffuse Intrinsic Pontine Glioma therapeutic market.

Diffuse Intrinsic Pontine Glioma (DIPG) Therapeutics Landscape

Diffuse Intrinsic Pontine Glioma treatment often comprises a combination of several therapies, including surgery, chemotherapy, radiation, or stereotactic radiosurgery followed by additional/adjuvant treatments, such as chemotherapy or radiation therapy, after surgery.

The most effective and initial treatment for patients with DIPG includes the use of radiation therapy. In cases where surgical resection of a tumor is possible, then surgery is considered as first-line treatment. The goal of surgery is to obtain tissue to determine the tumor type and to remove as much tumor as possible without causing more symptoms for the person.

The first step in treating DIPG is a surgical procedure to make a diagnosis, relieve pressure on the brain, and remove as many tumors as possible safely. DIPG surgery is performed to achieve a “maximum safe resection,” or remove as much of the tumor as possible without causing lasting neurological damage. In most cases, it is not possible to remove the entire tumor, so additional treatment with radiation therapy and/or chemotherapy is necessary.

Chemotherapy is one of the main forms of treatment for DIPG. When a tumor cannot be surgically removed, chemotherapy is used as a primary treatment. Chemotherapy may be used in infants and very young children to delay radiation therapy until the age of 3 or 4. At that point, the child’s brain is more fully developed and better able to tolerate radiation therapy. The drugs used before surgery to shrink the tumor are known as neoadjuvant therapy, and the ones used after surgery to kill additional cancer cells are referred to as adjuvant therapy.

Several major pharma and biotech companies are developing therapies for Diffuse Intrinsic Pontine Glioma. Currently, Midatech is leading the therapeutics market with its Diffuse Intrinsic Pontine Glioma drug candidates in the most advanced stage of clinical development.

Diffuse Intrinsic Pontine Glioma (DIPG) Companies Actively Working in the Therapeutic Market Include:


Kazia Therapeutics

Kintara Therapeutics

Oncotelic Therapeutics

Antisense Pharma

Y-mAbs Therapeutics

PTC Therapeutics

Celgene Corporation

And Many Others

Emerging and Marketed Diffuse Intrinsic Pontine Glioma (DIPG) Drugs Covered in the Report Include:

MTX 110: Midatech

Paxalisib: Kazia Therapeutics

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Diffuse Intrinsic Pontine Glioma Companies Working in the Market @ 


Analysis of Emerging Diffuse Intrinsic Pontine Glioma Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) 

Pre-clinical and Discovery stage candidates

Discontinued and inactive candidates

Route of Administration

Diffuse Intrinsic Pontine Glioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as











Molecule Type

Products have been categorized under various Molecule types such as



Small molecule

Learn How the Diffuse Intrinsic Pontine Glioma Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @


Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Diffuse Intrinsic Pontine Glioma Treatment Patterns

4. Diffuse Intrinsic Pontine Glioma – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Diffuse Intrinsic Pontine Glioma Late Stage Products (Phase-III)

7. Diffuse Intrinsic Pontine Glioma Mid-Stage Products (Phase-II)

8. Diffuse Intrinsic Pontine Glioma Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Diffuse Intrinsic Pontine Glioma Discontinued Products

13. Diffuse Intrinsic Pontine Glioma Product Profiles

14. Major Diffuse Intrinsic Pontine Glioma Companies in the Market

15. Key Products in the Diffuse Intrinsic Pontine Glioma Therapeutics Segment

16. Dormant and Discontinued Products

17. Diffuse Intrinsic Pontine Glioma Unmet Needs

18. Diffuse Intrinsic Pontine Glioma Future Perspectives

19. Diffuse Intrinsic Pontine Glioma Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @ 




About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Elevate your market presence and strategy in the medical devices industry through our meticulous market research services, driving growth and precision in every decision @ Medical Devices Market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

%d bloggers like this: